Stephens Inc. AR Reduces Holdings in Bioventus Inc. (NYSE:BVS)

Stephens Inc. AR trimmed its stake in Bioventus Inc. (NYSE:BVS - Free Report) by 51.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 26,775 shares of the company's stock after selling 28,925 shares during the period. Stephens Inc. AR's holdings in Bioventus were worth $281,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Royce & Associates LP bought a new position in shares of Bioventus in the 3rd quarter worth about $8,337,000. Segall Bryant & Hamill LLC bought a new position in shares of Bioventus in the 3rd quarter worth about $4,515,000. Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of Bioventus in the 3rd quarter worth about $3,092,000. State Street Corp increased its stake in Bioventus by 38.8% during the 3rd quarter. State Street Corp now owns 676,501 shares of the company's stock valued at $8,084,000 after purchasing an additional 189,216 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its stake in Bioventus by 228.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 253,740 shares of the company's stock valued at $3,032,000 after purchasing an additional 176,442 shares in the last quarter. 62.94% of the stock is owned by hedge funds and other institutional investors.

Bioventus Stock Performance

Shares of BVS stock traded down $0.37 during trading hours on Thursday, reaching $9.95. The company had a trading volume of 322,403 shares, compared to its average volume of 272,551. The business has a fifty day moving average price of $10.37 and a 200-day moving average price of $10.83. Bioventus Inc. has a one year low of $3.90 and a one year high of $14.38. The firm has a market cap of $807.44 million, a PE ratio of -16.31 and a beta of 0.85. The company has a debt-to-equity ratio of 1.85, a quick ratio of 0.99 and a current ratio of 1.41.

Wall Street Analysts Forecast Growth

BVS has been the subject of a number of analyst reports. Canaccord Genuity Group raised their price objective on shares of Bioventus from $12.00 to $15.00 and gave the company a "buy" rating in a research note on Wednesday, November 6th. JPMorgan Chase & Co. upgraded shares of Bioventus from an "underweight" rating to a "neutral" rating and raised their price objective for the company from $12.00 to $13.00 in a research note on Tuesday, December 17th.

Insider Transactions at Bioventus

In other news, SVP Katrina J. Church sold 2,535 shares of Bioventus stock in a transaction that occurred on Monday, December 23rd. The shares were sold at an average price of $10.53, for a total value of $26,693.55. Following the completion of the sale, the senior vice president now directly owns 47,264 shares in the company, valued at $497,689.92. The trade was a 5.09 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Robert E. Claypoole sold 28,786 shares of Bioventus stock in a transaction that occurred on Monday, January 13th. The stock was sold at an average price of $9.10, for a total transaction of $261,952.60. Following the completion of the sale, the chief executive officer now owns 64,964 shares of the company's stock, valued at $591,172.40. This represents a 30.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 42,054 shares of company stock worth $401,665 over the last three months. 32.90% of the stock is currently owned by company insiders.

Bioventus Company Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.